Moreover, CTLA-4 expressed by breast cancer cells may attenuate CD80/86 DC expression and subsequent restricted maturity can hinder proper CD8+ and Th1 CD4+ effector cells [69]. The gene discussed is CD8A; the disease is breast carcinoma.